These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7690462)

  • 1. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group.
    Saag MS; Emini EA; Laskin OL; Douglas J; Lapidus WI; Schleif WA; Whitley RJ; Hildebrand C; Byrnes VW; Kappes JC
    N Engl J Med; 1993 Oct; 329(15):1065-72. PubMed ID: 7690462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
    Eron JJ; Benoit SL; Jemsek J; MacArthur RD; Santana J; Quinn JB; Kuritzkes DR; Fallon MA; Rubin M
    N Engl J Med; 1995 Dec; 333(25):1662-9. PubMed ID: 7477218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
    N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
    Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
    N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
    N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
    N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.
    Danner SA; Carr A; Leonard JM; Lehman LM; Gudiol F; Gonzales J; Raventos A; Rubio R; Bouza E; Pintado V
    N Engl J Med; 1995 Dec; 333(23):1528-33. PubMed ID: 7477167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
    N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of zidovudine in primary human immunodeficiency virus infection.
    Kinloch-De Loës S; Hirschel BJ; Hoen B; Cooper DA; Tindall B; Carr A; Saurat JH; Clumeck N; Lazzarin A; Mathiesen L
    N Engl J Med; 1995 Aug; 333(7):408-13. PubMed ID: 7616989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.
    Staszewski S; Massari FE; Kober A; Göhler R; Durr S; Anderson KW; Schneider CL; Waterbury JA; Bakshi KK; Taylor VI
    J Infect Dis; 1995 May; 171(5):1159-65. PubMed ID: 7538547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of low-dose zidovudine in human immunodeficiency virus infection.
    Collier AC; Bozzette S; Coombs RW; Causey DM; Schoenfeld DA; Spector SA; Pettinelli CB; Davies G; Richman DD; Leedom JM
    N Engl J Med; 1990 Oct; 323(15):1015-21. PubMed ID: 1977080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
    Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA
    N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Cheeseman SH; Havlir D; McLaughlin MM; Greenough TC; Sullivan JL; Hall D; Hattox SE; Spector SA; Stein DS; Myers M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):141-51. PubMed ID: 7530585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.
    Markowitz M; Saag M; Powderly WG; Hurley AM; Hsu A; Valdes JM; Henry D; Sattler F; La Marca A; Leonard JM
    N Engl J Med; 1995 Dec; 333(23):1534-9. PubMed ID: 7477168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.